Data Insights

Cabometyx by Exelixis for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Cabometyx by Exelixis for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Cabometyx by Exelixis for Gastric Cancer: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Gastric Cancer

Data Insights

Cabometyx by Exelixis for Neuroendocrine Tumors: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Neuroendocrine Tumors

Data Insights

Cabometyx by Exelixis for Wilms' Tumor (Nephroblastoma): Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Wilms' Tumor (Nephroblastoma). According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Wilms' Tumor (Nephroblastoma)

Data Insights

Cabometyx by Exelixis for Rhabdomyosarcoma: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Rhabdomyosarcoma

Data Insights

Cabometyx by Exelixis for Osteosarcoma: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Osteosarcoma

Data Insights

Cabometyx by Exelixis for Ovarian Cancer: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Ovarian Cancer

Data Insights

Cabometyx by Exelixis for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase III for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)

Data Insights

Cabometyx by Exelixis for Metastatic Colorectal Cancer: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Metastatic Colorectal Cancer

Data Insights

Cabometyx by Exelixis for Solid Tumor: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Solid Tumor

Data Insights

Cabometyx by Exelixis for Non-Small Cell Lung Cancer: Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Non-Small Cell Lung Cancer